Target Price | $1.02 |
Price | $0.03 |
Potential |
3,357.63%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Petros Pharmaceuticals Inc 2026 .
The average Petros Pharmaceuticals Inc target price is $1.02.
This is
3,357.63%
register free of charge
$1.05
3,459.32%
register free of charge
$1.01
3,323.73%
register free of charge
|
|
A rating was issued by 7 analysts: 6 Analysts recommend Petros Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Petros Pharmaceuticals Inc stock has an average upside potential 2026 of
3,357.63%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 5.11 | 5.59 |
12.20% | 9.30% | |
Net Margin | -524.46% | -8.36% |
121.03% | 98.41% |
3 Analysts have issued a sales forecast Petros Pharmaceuticals Inc 2025 . The average Petros Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Petros Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Petros Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -83.46 | -1.11 |
47.41% | 98.67% | |
P/E | negative | |
EV/Sales | 0.86 |
3 Analysts have issued a Petros Pharmaceuticals Inc forecast for earnings per share. The average Petros Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Petros Pharmaceuticals Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.